StockNews.AI
LUCD
StockNews.AI
14 days

Lucid Diagnostics to Participate in Upcoming Investor Conferences

1. Lucid Diagnostics participates in upcoming investor conferences. 2. Conferences include Needham Virtual MedTech and Canaccord Genuity Growth Conference. 3. Live webcasts will be available for investor access post-conferences. 4. Lucid focuses on cancer prevention through innovative diagnostic tools. 5. EsoGuard® detects esophageal precancer in at-risk GERD patients.

6m saved
Insight
Article

FAQ

Why Bullish?

Participation in investor conferences can enhance visibility and attract investment interest. Similar past conference participations have positively correlated with stock price increases in the biotech sector.

How important is it?

The conferences provide a platform for Lucid to showcase its innovations and attract potential partnerships, which is essential for growth in the diagnostic market.

Why Short Term?

Increased investor attention and engagement often lead to short-term stock price fluctuations. Historical data shows spikes in stock prices following significant investor events.

Related Companies

PAVM
Resources Blog Journalists Client Login Send a Release News Products Contact , /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that management will participate in the following upcoming investor conferences: 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference 1x1 Meetings: August 11-12, 2025 Location: Virtual Canaccord Genuity 45th Annual Growth Conference Fireside Chat: August 13, 2025, at 2:30 PM ET Location: Boston, MA The live and archived webcast of the Canaccord Genuity fireside chat can be accessed by clicking here or by visiting the Investor Relations Section of the Lucid Diagnostics website.  A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast. About Lucid DiagnosticsLucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients. For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com. SOURCE Lucid Diagnostics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In Also from this source

Related News